Your data. DELIVERED.

Full-service preclinical CRO specialized in oncology and skeletal disease models

Are you looking for something special?

Welcome to
Pharmatest

PHARMATEST offers preclinical in vitro assays, in vivo efficacy models and ex vivo bone analysis services in the fields of oncology and skeletal diseases.

We are the leading experts in combining cancer and bone biology having special expertise in bone metastases. Our cancer models cover comprehensive portfolio of xenograft, syngeneic and immuno-oncology models. We have substantial experience in performing studies with targeted radionuclide therapy in both, in vitro and in vivo studies.

Our models of skeletal diseases include osteoclast and osteoblast in vitro studies and animal models of osteoporosis, osteoarthritis and rare bone disease.

Ex vivo services cover complete histomorphometry and non-invasive imaging for bone and soft tissue and large panel of biomarkers for preclinical and clinical samples. Via our large collaboration network, we can also offer GLP-toxicology studies for you.

Our services have been developed with just one goal in mind – to make your nonclinical drug development faster and more predictive. Our mission is to offer clinically predictive preclinical models in order to decrease the currently high failure rates in clinical trials.

All studies are performed at modern state-of-the-art research laboratories by our committed specialists with exceptionally strong scientific and technical expertise. Our carefully validated and optimized models have high clinical predictivity to save your time and costs. We utilize our expert knowledge and experience to select the correct model for you or customize solutions specifically to your needs. During the past 20 years, we have served hundreds of clients globally by testing thousands of their compounds.

Skeletal disease models

Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis.

Bone analysis

Pharmatest’s standard study setups in different disease models include different combinations of the bone analysis methods that can also be used as stand-alone services.

Clinical biomarkers

Pharmatest provides full-service re­search solutions for fast and reliable measure­ment of biomarkers in clinical (human) samples.

Radiopharmaceuticals testing

Pharmatest has performed a large amount of studies and acquired special expertise in testing α-emitters such as Ra-223, Ra-224 and Th-227.

Cancer models

Pharmatest is a CRO specialized in orthotopic and metastasis models, and as bone experts we have special expertise in bone metastasis models.

Skeletal disease models

Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis.

Bone analysis

Pharmatest’s standard study setups in different disease models include different combinations of the bone analysis methods that can also be used as stand-alone services.

Clinical biomarkers

Pharmatest provides full-service re­search solutions for fast and reliable measure­ment of biomarkers in clinical (human) samples.

Radiopharmaceuticals testing

Pharmatest has performed a large amount of studies and acquired special expertise in testing α-emitters such as Ra-223, Ra-224 and Th-227.

News

Testimonials

Dr. Karl ZiegelbauerSVP Therapeutic Research Groups, Pharmaceuticals Division, Bayer Pharma AG, Germany
Read More
"Bayer has worked for several years with Pharmatest and we are very impressed about the high quality of the work they have done for us."
Dr. Hubert ChenChief Medical Officer, Pfenex Inc., USA
Read More
“It was a great pleasure working with Pharmatest. The scientific expertise and advice offered by the Pharmatest team were top notch. There was excellent, proactive communication from the very beginning of the project, which finished on time and within budget. I have no hesitations in recommending Pharmatest as a high-quality CRO for preclinical services in skeletal diseases.”
Dr. Dana T. AftabExecutive Vice President, Business Operations, Exelixis Inc., USA
Read More
"Exelixis has been working with Pharmatest since 2011, and we have been very pleased with their excellent data quality, detailed and thorough reports, and highly professional and knowledgeable staff.”
Dr. Satu VainikkaCEO, Valirx Plc, UK
Read More
"Pharmatest has been our preferred supplier of preclinical proof-of-concept studies for some time now and we are very satisfied about the high quality and scientific expertise that they provide."
Dr. Leslie HolsingerVice President of Biology, Virobay Inc., USA
Read More
"Virobay has worked with Pharmatest on both in vitro and in vivo model analysis of drug candidates and we are very pleased with the excellent quality of their work and the high level of scientific expertise they provide to our studies.”
Hanne Heidenheim BakM.Sc. Pharm, Senior Project Director, Head of Project Management, Zealand Pharma A/S, Denmark
Read More
"It has been a pleasure working with the Pharmatest team. You have been an excellent communicator, always informing us promptly on changes or questions that have come up and providing great feedback to our questions. We certainly experience Pharmatest as a very competent company with very professional employees."
Dr. Pekka KallioHead of Oncology Research, Orion Oyj, Finland
Read More
“Orion started to use services of Pharmatest more than 10 years ago, and we are happy about the excellent scientific quality of their work and reporting.”
Dr. Jean-Baptiste MarchandHead of Proteins Science Group, Transgene, France
Read More
”Transgene and Pharmatest have successfully collaborated since 2009 for the in vitro and in vivo preclinical evaluation of TG’s monoclonal platform in different skeletal diseases. Transgene was particularly impressed by the high professionalism of Pharmatest’s scientist staff, who participated actively nearby our teams in the designs, execution and analysis of the experiments.”
Dr. Nick FlinnHead of Pre-clinical Development, Amura Therapeutics, England
Read More
"Amura has worked closely with Pharmatest for over a decade in the areas of bone turnover and bone metastases. Pharmatest has provided support and advice in addition to a first class in vitro and in vivo screening service for the analysis and progression of Amura's drug candidates. We are always impressed with the excellent quality of their work and the high level of scientific expertise they provide to our studies.”